127 related articles for article (PubMed ID: 38244348)
1. Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma.
Petrillo A; Derks S; Smyth EC
ESMO Open; 2024 Feb; 9(2):102229. PubMed ID: 38244348
[No Abstract] [Full Text] [Related]
2. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.
Zhou KI; Hanks BA; Strickler JH
J Gastrointest Cancer; 2023 Dec; ():. PubMed ID: 38133871
[TBL] [Abstract][Full Text] [Related]
3. Controversies in upper GI oncology: early-onset gastric cancer.
Petrillo A; Alsina M; Ben-Aharon I
ESMO Open; 2024 May; 9(5):102925. PubMed ID: 38663169
[No Abstract] [Full Text] [Related]
4. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastroesophageal cancer in a large Belgian cohort.
De Meulder S; Sagaert X; Brems H; Brekelmans C; Nafteux P; Topal B; Verslype C; Tejpar S; Van Cutsem E; Dekervel J
Acta Gastroenterol Belg; 2022; 85(1):1-5. PubMed ID: 35304987
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
7. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
Klein O; Brown WA; Saxon S; Haydon A
Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
[TBL] [Abstract][Full Text] [Related]
8. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
9. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
11. MSI Analysis in Solid and Liquid Biopsies of Gastroesophageal Adenocarcinoma Patients: A Molecular Approach.
Boldrin E; Piano MA; Alfieri R; Mazza M; Vassallo L; Scapinello A; Pilati P; Curtarello M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298864
[TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux disease in chronic renal failure patients with upper GI symptoms: multivariate analysis of pathogenetic factors.
Cekin AH; Boyacioglu S; Gursoy M; Bilezikci B; Gur G; Akin ED; Ozdemir N; Yilmaz U
Am J Gastroenterol; 2002 Jun; 97(6):1352-6. PubMed ID: 12094849
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
14. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
16. Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability.
Li JH; Shi XZ; Lv S; Liu M; Xu GW
World J Gastroenterol; 2005 Jul; 11(28):4363-6. PubMed ID: 16038035
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients.
Hiltner T; Kohlruss M; Herz AL; Lorenzen S; Novotny A; Hapfelmeier A; Jesinghaus M; Slotta-Huspenina J; Sisic L; Gaida MM; Weichert W; Ott K; Keller G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7651-7662. PubMed ID: 37000259
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
[TBL] [Abstract][Full Text] [Related]
19. Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials.
Zhuo ZG; Deng HY; Song TN; Alai GH; Shen X; Lin YD
Ann Palliat Med; 2020 Sep; 9(5):2524-2537. PubMed ID: 33065778
[TBL] [Abstract][Full Text] [Related]
20. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
